Unexpected Role for Epigenetic Enzymes in Cancer
News Dec 06, 2016
To better understand how cancer initiates and spreads, Yale associate professor of pathology Qin Yan turned to the field of epigenetics, which examines changes in the expression of genes and proteins that do not affect the underlying genetic codes.
In a Yale-led study, Yan and his co-authors focused on a family of enzymes — known as KDM5 — that had been shown in previous studies to be involved in cancer cell growth and spreading.
First author Lauren Blair, an associate research scientist, conducted biochemical studies with Baker’s yeast as the model system, and identified an unexpected role of these enzymes in the process by which genetic messages are interpreted by yeast cells. Further studies showed that the enzymes’ role as regulators of this process is also important for human tumor cells to grow and spread. The finding could lead to a therapy that inhibits the enzyme, and tumor growth, in cancer patients.
Story from Yale University. Original piece written by Ziba Kashef. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Blair, L. P., Liu, Z., Labitigan, R. L. D., Wu, L., Zheng, D., Xia, Z., … Yan, Q. (2016). KDM5 lysine demethylases are involved in maintenance of 3’UTR length. Science Advances, 2(11),. doi:10.1126/sciadv.1501662
Holding Infants – or not – Can Leave Traces on Their GenesNews
Children who have been more distressed as infants and have received less physical contact have a molecular profile that is underdeveloped for their age – pointing to the possibility that they are lagging biologically.READ MORE
Revealing the Role of the Centromere in Down SyndromeNews
The centromere plays a crucial role in the everyday cell division that keeps us healthy but is also potentially involved in birth defects, cancers and other diseases that arise from cell division problems.READ MORE
Cambridge Epigenetix Appoints Professor Mark Dawson as Scientific AdvisorNews
Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, announced the appointment of leading epigenetics-based therapeutics specialist, Professor Mark Dawson to its Scientific Advisory Board (SAB).READ MORE